Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership
Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC)
Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023
GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20%
Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/
Disclaimer: Inten
